Phase 4 mucosal sIgA response after LAIV nasal spray
Summary
A Phase 4 clinical trial (NCT07545564) registered April 22, 2026, will evaluate mucosal-specific sIgA antibody geometric mean titer (GMT) responses and the achievement of 2-fold and 4-fold increases in nasal mucosal sIgA antibodies following administration of a nasal spray Live Attenuated Influenza Vaccine (LAIV). The study includes LAIV and placebo intervention arms and is categorised under the condition of Influenza.
“Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
A new Phase 4 clinical trial registration (NCT07545564) has been posted to ClinicalTrials.gov by the NIH. The study will assess mucosal-specific sIgA antibody geometric mean titer (GMT) as the primary outcome, measuring both absolute GMT and the proportion of participants achieving 2-fold and 4-fold increases from baseline following LAIV nasal spray vaccination, compared to placebo.
For pharmaceutical sponsors, contract research organisations, and clinical investigators involved in influenza vaccine development, this post-marketing study registration signals an active LAIV programme entering the immunogenicity evaluation phase. Sites currently recruiting or considering participation should review eligibility criteria and investigator requirements upon availability of the full ClinicalTrials.gov record.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine
Phase 4 NCT07545564 Kind: PHASE4 Apr 22, 2026
Abstract
Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination
Conditions: Influenza
Interventions: LAIV, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.